Ritonavir is a protease inhibitor and is used with other protease inhibitors.
| FactSnippet No. 1,424,666 |
12 Facts About Ritonavir
2.
Ritonavir was patented in 1989 and came into medical use in 1996.
| FactSnippet No. 1,424,667 |
3.
Ritonavir capsules were approved as a generic medication in the United States in 2020.
| FactSnippet No. 1,424,668 |
4.
Ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1-infected patients.
| FactSnippet No. 1,424,669 |
5.
Ritonavir induces CYP1A2 and inhibits the major P450 isoforms 3A4 and 2D6.
| FactSnippet No. 1,424,670 |
6.
Ritonavir was originally developed as an inhibitor of HIV protease, one of a family of pseudo-C2-symmetric small molecule inhibitors.
| FactSnippet No. 1,424,671 |
7.
Ritonavir is rarely used for its own antiviral activity but remains widely used as a booster of other protease inhibitors.
| FactSnippet No. 1,424,672 |
8.
Ritonavir was demonstrated to have an in vitro potency of EC50=0.
| FactSnippet No. 1,424,673 |
9.
Ritonavir was initially derived from a moderately potent and orally bioavailable small molecule, A-80987.
| FactSnippet No. 1,424,674 |
10.
Ritonavir serves to slow down metabolism of nirmatrelvir by cytochrome enzymes to maintain higher circulating concentrations of the main drug.
| FactSnippet No. 1,424,675 |
11.
Ritonavir was originally dispensed as a capsule that did not require refrigeration.
| FactSnippet No. 1,424,676 |
12.
Ritonavir produced in a solid dispersion by melt-extrusion was found to remain in form I, and was re-introduced commercially in 2010.
| FactSnippet No. 1,424,677 |